Global Cell and Gene Therapy Drug Delivery Devices Market Size is valued at USD 1.1 Bn in 2024 and is predicted ato reach USD 2.9 Bn by the year 2034 at a 9.6% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
The demand for cell and gene therapy drug delivery devices market is enhancing as there is an increase in the number of patients suffering from cancer, diabetes, and other chronic diseases. Therefore, there is a high need of developing affordable and cost-effective cell and gene therapies. Cell and gene therapy is a clinical procedure of modifying genetic material for the treatment of various diseases. Drug Delivery devices have the capacity to perform multiple functions with the highest degree of smartness. Cell and Gene Therapy Drug Delivery Devices are beneficial in the treatment of respiratory diseases, diabetes, and other cardiovascular disorders.
Spreading awareness regarding the benefits of cell and gene therapy drug delivery devices is expected to propel the product demand. Furthermore, fast adoption of advanced technologies, an invention of new devices according to patient’s requirements, increasing government initiatives for research and development of new therapies and devices, high prevalence of chronic diseases, rising number of clinical trials, and creation of smartphone applications will also help to upscale this market. However, the high cost of manufacturing systems, lack of standard therapy protocols, complex procedures, and shortage of skilled professionals are limiting the growth of this market.
The cell and gene therapy drug delivery devices market can be segmented on the basis of products, Commercialized Drugs, and Regions. On the basis of products, the market can be sub-divided into Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Pre-Filled Syringe, and Infusion Bags. On the basis of Commercialized Drugs, the market is sub-segmented into Luxturna, Kymriah, Provenge, Zolgensma, Yescarta, and Strimvelis. Commercialized Drugs segment is expected to dominate this market, as these drugs are modified and prepared according to patient’s requirements. In terms of geography, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Out of these regions, North America is expected to dominate the market over the forecast period (2019-2031).
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.1 Bn |
|
Revenue Forecast In 2034 |
USD 2.9 Bn |
|
Growth Rate CAGR |
CAGR of 9.6% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Thousands and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Products, By Commercialized Drugs |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Bausch & Lomb Incorporated., Amgen Inc., Becton, Dickinson and Company, Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.), Dendreon Pharmaceuticals LLC., Bluebird bio, Inc., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cells Institute, Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., Kolon TissueGene, Inc., Vericel Corporation, uniQure N.V., and Others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell and Gene Therapy Drug Delivery Devices Market Snapshot
Chapter 4. Global Cell and Gene Therapy Drug Delivery Devices Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Major Funding Investments in Cell and Gene Therapy Industry
4.8. COVID 19 Impact Analysis
Chapter 5. Market Segmentation 1: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value & Volume) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Subretinal Injection Cannula
5.2.2. Extension Tube
5.2.3. Intravenous Catheter
5.2.4. Sterile Insulin Syringe
5.2.5. Pre-Filled Syringe
5.2.6. Infusion Bags
Chapter 6. Cell and Gene Therapy Drug Delivery Devices Market Segmentation 2: By Commercialized Drugs Estimates & Trend Analysis
6.1. By Commercialized Drugs Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value & Volume) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Commercialized Drugs:
6.2.1. Luxturna
6.2.2. Kymriah
6.2.3. Provenge
6.2.4. Zolgensma
6.2.5. Yescarta
6.2.6. Strimvelis
Chapter 7. Cell and Gene Therapy Drug Delivery Devices Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts By Products, 2021-2034
7.1.2. North America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts By Commercialized Drugs, 2021-2034
7.1.3. North America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, 2021-2034
7.2.2. Europe Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, 2021-2034
7.2.3. Europe Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, 2021-2034
7.3.2. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, 2021-2034
7.3.3. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, (US$ Million) 2021-2034
7.4.2. Latin America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, (US$ Million) 2021-2034
7.4.3. Latin America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, (US$ Million) 2021-2034
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. MEA
7.5.1. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, (US$ Million) 2021-2034
7.5.2. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, (US$ Million) 2021-2034
7.5.3. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, (US$ Million) 2021-2034
7.5.4. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, (US$ Million) 2021-2034
7.5.4.1. South Africa
7.5.4.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Amgen Inc.
8.2.2. Bausch & Lomb Incorporated.
8.2.3. Becton, Dickinson and Company
8.2.4. Bluebird bio, Inc.
8.2.5. Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
8.2.6. Dendreon Pharmaceuticals LLC.
8.2.7. Helixmith Co., Ltd (ViroMed Co., Ltd)
8.2.8. Human Stem Cells Institute
8.2.9. Kite Pharma, Inc.
8.2.10. Kolon TissueGene, Inc.
8.2.11. Novartis AG
8.2.12. Orchard Therapeutics plc.
8.2.13. Pfizer, Inc.
8.2.14. Renova Therapeutics
8.2.15. Spark Therapeutics, Inc.
8.2.16. uniQure N.V.
8.2.17. Vericel Corporation
8.3. List of Other Prominent Players
Global Cell and Gene Therapy Drug Delivery Devices Market Size (Value & Volume) & Forecasts and Trend Analyses, 2019 to 2030 Based on Products
Global Cell and Gene Therapy Drug Delivery Devices Market Size (Value & Volume) & Forecasts and Trend Analyses, 2019 to 2030 Based on Commercialized Drugs
Global Cell and Gene Therapy Drug Delivery Devices Market Size (Value & Volume) & Forecasts and Trend Analyses, 2019 to 2030 Based on Region
Europe Cell and Gene Therapy Drug Delivery Devices Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2019 to 2030
North America Cell and Gene Therapy Drug Delivery Devices Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2019 to 2030
Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2019 to 2030
Latin America Cell and Gene Therapy Drug Delivery Devices Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2019 to 2030
Middle East & Africa Cell and Gene Therapy Drug Delivery Devices Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2019 to 2030
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
